Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM
Latest Information Update: 03 May 2024
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Therapeutic Use
- Sponsors Amgen; Bristol-Myers Squibb; Celgene International SARL
- 06 Jun 2023 Results reporting post-induction and MRD response presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 04 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2018 New trial record